1 / 45

Antiepileptic Drugs and Suicidality: Statistical Review

Antiepileptic Drugs and Suicidality: Statistical Review. Mark Levenson, Ph.D. Statistical Safety Reviewer Quantitative Safety and Pharmacoepidemiology Group Division of Biometrics 6/CDER/FDA

qamra
Télécharger la présentation

Antiepileptic Drugs and Suicidality: Statistical Review

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antiepileptic Drugs and Suicidality: Statistical Review Mark Levenson, Ph.D. Statistical Safety Reviewer Quantitative Safety and Pharmacoepidemiology Group Division of Biometrics 6/CDER/FDA Joint Meeting of Peripheral and Central Nervous System Drugs Advisory Committee and Psychopharmacologic Drugs Advisory Committee July 10, 2008

  2. Outline • Objectives • Analysis plan • Endpoints • Populations and subgroups • Methods • Results • Trial and patient summaries • Primary, secondary, sensitivity analyses • Subgroups • Conclusions

  3. Objectives Primary Objective Examine whether 11 antiepileptic drugs as a group are associated with increased risk of suicidality relative to placebo in randomized placebo-controlled trials Secondary Objectives Examine whether the risk of suicidality varies byindividual drug, drug groups, studied indication, and demographics

  4. Outline • Objectives • Analysis plan • Endpoints • Populations and subgroups • Methods • Results • Trial and patient summaries • Primary, secondary, sensitivity analyses • Subgroups • Conclusions

  5. Primary Endpoint Suicidal Behavior or Ideation • Completed suicide • Suicide attempt • Preparatory acts • Suicidal ideation

  6. Secondary Endpoints Suicidal Behavior • Completed suicide • Suicide attempt • Preparatory acts Suicidal Ideation • Suicidal ideation

  7. Primary Analysis Population • Trial inclusion criteria • Randomized parallel placebo-controlled • Not a withdrawal design • Open label-extension periods excluded • Duration ≥ 7 days • ≥ 20 patients in each arm • Patient inclusion criteria • Age ≥ 5 years

  8. Subgroups and Special Populations

  9. Subgroups • 11 individual drugs • Drug groups • Sodium Channel Blocking Drugs Carbamazepine, Lamotrigine, Oxcarbazepine, Topiramate, Zonisamide • GABAergic Drugs and GABAmimetic Drugs Divalproex, Gabapentin, Pregabalin, Tiagabine, Topiramate • Carbonic Anhydrase Inhibitors Topiramate, Zonisamide

  10. Subgroups • Studied indication • Epilepsy • Psychiatric Indications • Other • Demographics • Age (5-17, 18-24, 25-30, 31-64, ≥65) • Gender • Race • Setting (in-patient component, out-patient only) • Location (North America, Non-North America)

  11. Primary Analysis Method • Exact method for common odds ratio • Allows trials to have different background rates of events • Handles low event counts (sparse data) • Does not make use of trials with no events (zero-event trials) • Assumes a common odds ratio for trials • Details • Unit of analysis: patient • Primary display: odds ratio (OR) and 95% CI

  12. Sensitivity Analysis • Zero-event trials • Mantel-Haenszel risk difference • Trial OR heterogeneity • Generalized linear mixed model (GLMM) with random trial effect • Examination of large Mantel-Haenszel weights • Duration differences • Exact method of incident rate ratio based on patient-years of exposure

  13. Exploratory Analysis • Kaplan-Meier incidence curves • Life-table hazard estimates

  14. Outline • Objectives • Analysis plan • Endpoints • Populations and subgroups • Methods • Results • Trial and patient summaries • Primary, secondary, sensitivity analyses • Subgroups • Conclusions

  15. Results: Trial and Patient Summaries

  16. Primary Analysis Group • 199 placebo-controlled trials • 43,892 total patients • 27,863 drug-treated • 16,029 placebo

  17. Trials and Patients by Drug

  18. Nominal Trial Duration (Weeks) • Mean = 14.2 • Median =12 • Range = (1, 112) • 90% of trials in (3, 39)* • 50% of trial in (8, 16)† * (5%, 95%) quantiles † (25%, 75%) quantiles

  19. Trials by Indication Group and Therapy

  20. Patients by Drug and Indication

  21. Patient Baseline Demographics

  22. Patient Baseline Demographics

  23. Patient Baseline Demographics • No notable differences between drug and placebo patients for baseline demographics

  24. Patient Treatment Duration and Discontinuation * Least-squares means. P-value <.001 for difference in treatment groups † P-value <.001 for difference in treatment groups

  25. Results: Primary, Secondary, and Sensitivity Analyses

  26. Suicidal Behavior or Ideation Placebo: 38/16029 of patients had event (0.24%) Drug: 104/27863 of patients had event (0.37%) 66/199 = 33% trials had at least one event

  27. Most Critical Event by Type and Treatment Arm

  28. Suicidal Behavior or Ideation Odds Ratio Estimates

  29. Suicidal Behavior versus Suicidal Ideation Odds Ratio Estimates

  30. Suicidal Behavior or Ideation Kaplan-Meier

  31. Suicidal Behavior or Ideation Risk Difference Estimates

  32. Sensitivity Analyses Results were robust to • Inclusion of trials with no events • Possibility of trial heterogeneity • Difference in treatment duration between treatment groups

  33. Results: Subgroups

  34. Suicidal Behavior or Ideation Odds Ratio Estimates by Drug Group

  35. Suicidal Behavior or Ideation Odds Ratio Estimates by Indication Group

  36. Suicidal Behavior or Ideation Event Rates, Risk Measures by Indication * Patients with events per 1000 patients

  37. Suicidal Behavior or Ideation Odds Ratio Estimates by Age Group

  38. Suicidal Behavior or Ideation Odds Ratio Estimates by Post-Hoc Age Group

  39. Suicidal Behavior or Ideation Odds Ratio Estimates by Gender

  40. Suicidal Behavior or Ideation Odds Ratio Estimates by Race Group

  41. Suicidal Behavior or Ideation Odds Ratio Estimates by Setting

  42. Suicidal Behavior or Ideation Odds Ratio Estimates by Location

  43. Outline • Objectives • Analysis plan • Endpoints • Populations and subgroups • Methods • Results • Trial and patient summaries • Primary, secondary, sensitivity analyses • Subgroups • Conclusions

  44. Conclusions (1) 11 antiepileptic drugs as a group had a statistically significant effect on Suicidal Behavior or Ideation OR = 1.80 (95% CI: 1.24, 2.66) 8 of 11 drugs had estimated OR > 1 Attributed risk: 1.9 per 1000 (95% CI: 0.6, 3.9) additional patients with Suicidal Behavior or Ideation events from the drugs compared to placebo

  45. Conclusions (2) Higher drug hazard seen over extended period (not statistically evaluated) Epilepsy had highest estimated OR Epilepsy and psychiatric indications had comparable RD Non-North America had notably higher OR Other subgroups (age, gender, race, setting, drug class) did not have notable effects Results were robust to analysis method

More Related